omaveloxolone
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic or Incurable Non-small Cell Lung Cancer
Conditions
Metastatic or Incurable Non-small Cell Lung Cancer, Relapsed, Refractory Melanoma
Trial Timeline
Dec 31, 2013 → Oct 1, 2015
NCT ID
NCT02029729About omaveloxolone
omaveloxolone is a phase 1 stage product being developed by AbbVie for Metastatic or Incurable Non-small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02029729. Target conditions include Metastatic or Incurable Non-small Cell Lung Cancer, Relapsed, Refractory Melanoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02029729 | Phase 1 | Completed |
Competing Products
20 competing products in Metastatic or Incurable Non-small Cell Lung Cancer